We are live on ! Find out more
QCG

Quadrant Capital Group Portfolio holdings

AUM $3.34B
1-Year Est. Return 29.16%
This Fund
S&P 500
This Quarter Est. Return
+4.25%
1 Year Est. Return
+29.16%
3 Year Est. Return
+77.72%
5 Year Est. Return
+92.59%
10 Year Est. Return
+303.92%
AUM
$3.31B
AUM Growth
+$234M
Cap. Flow
+$153M
Cap. Flow %
4.61%
Top 10 Hldgs %
29.6%
Holding
2,810
New
136
Increased
1,119
Reduced
861
Closed
104

Top Sells

Rank Stock Value
1
RDY icon
Dr. Reddy's Laboratories
RDY
+$3.19M
2
HD icon
Home Depot
HD
+$2.88M
3
COOP
Mr. Cooper
COOP
+$2.26M
4
PG icon
Procter & Gamble
PG
+$2.02M
5
CRM icon
Salesforce
CRM
+$1.9M

Sector Composition

Rank Sector Weight
1 Technology 22.8%
2 Financials 12.6%
3 Consumer Discretionary 7.91%
4 Healthcare 7.45%
5 Industrials 7.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IMVT icon
2351
Immunovant
IMVT
$8.23B
$5.39K ﹤0.01%
212
+132
+165% +$2.94K
PACS icon
2352
PACS Group
PACS
$7.45B
$5.38K ﹤0.01%
140
HLX icon
2353
Helix Energy Solutions
HLX
$1.42B
$5.37K ﹤0.01%
857
+353
+70% +$2.35K
CSR
2354
Centerspace
CSR
$937M
$5.34K ﹤0.01%
80
GTN icon
2355
Gray Television
GTN
$409M
$5.3K ﹤0.01%
1,095
+662
+153% +$3.24K
CARS icon
2356
Cars.com
CARS
$660M
$5.29K ﹤0.01%
434
-419
-49% -$4.87K
URG
2357
Ur-Energy
URG
$489M
$5.27K ﹤0.01%
3,794
+2,135
+129% +$3.16K
ASAN icon
2358
Asana
ASAN
$1.79B
$5.26K ﹤0.01%
384
+49
+15% +$674
OTEX icon
2359
Open Text
OTEX
$5.73B
$5.25K ﹤0.01%
161
ABCL icon
2360
AbCellera Biologics
ABCL
$1.6B
$5.24K ﹤0.01%
1,532
+103
+7% +$460
ATLC icon
2361
Atlanticus Holdings
ATLC
$1.58B
$5.22K ﹤0.01%
78
+43
+123% +$2.53K
CNDT icon
2362
Conduent
CNDT
$234M
$5.21K ﹤0.01%
2,715
+2,262
+499% +$4.96K
IDR icon
2363
Idaho Strategic Resources
IDR
$458M
$5.2K ﹤0.01%
129
+25
+24% +$955
WAY
2364
Waystar Holding Corp
WAY
$4.44B
$5.17K ﹤0.01%
158
-106
-40% -$3.78K
RYAM icon
2365
Rayonier Advanced Materials
RYAM
$573M
$5.17K ﹤0.01%
878
+463
+112% +$3.01K
BXC icon
2366
BlueLinx
BXC
$453M
$5.16K ﹤0.01%
84
+47
+127% +$3.03K
HBCP icon
2367
Home Bancorp
HBCP
$553M
$5.14K ﹤0.01%
89
-42
-32% -$2.34K
QXO
2368
QXO Inc
QXO
$14.7B
$5.13K ﹤0.01%
266
-41
-13% -$786
ACMR icon
2369
ACM Research
ACMR
$5.53B
$5.13K ﹤0.01%
+130
New +$4.84K
PRKS icon
2370
United Parks & Resorts
PRKS
$2.12B
$5.12K ﹤0.01%
141
+65
+86% +$2.7K
KROS icon
2371
Keros Therapeutics
KROS
$202M
$5.11K ﹤0.01%
251
SVV icon
2372
Savers
SVV
$1.48B
$5.09K ﹤0.01%
545
-74
-12% -$761
PTCT icon
2373
PTC Therapeutics
PTCT
$6.29B
$5.09K ﹤0.01%
+67
New +$4.87K
AHR icon
2374
American Healthcare REIT
AHR
$11.1B
$5.08K ﹤0.01%
108
LBTYK icon
2375
Liberty Global Class C
LBTYK
$3.27B
$5.05K ﹤0.01%
457

Similar funds

Quadrant Capital Group's Q4 2025 Portfolio in Review

As of Q4 2025, Quadrant Capital Group held 2,810 positions worth $3.31B, up 7.6% from $3.08B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Quadrant Capital Group deployed $153M of net new capital in Q4 2025, opening 136 new positions and adding to 1,119 existing holdings. Its largest new stake was Capital Group Global Growth Equity ETF: 18,866 shares worth $654K.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Dr. Reddy's Laboratories, an estimated $3.19M trimmed.

  • Quadrant Capital Group's largest Q4 2025 buy was Capital Group Global Growth Equity ETF: 18,866 shares worth $654K.
  • Quadrant Capital Group added most to State Street SPDR S&P 500 ETF Trust in Q4 2025, an estimated $16.7M increase.
  • Quadrant Capital Group's biggest Q4 2025 reduction was Dr. Reddy's Laboratories, cutting an estimated $3.19M.
  • Quadrant Capital Group fully exited Mr. Cooper in Q4 2025, selling an estimated $2.26M.
  • Quadrant Capital Group's ten largest holdings make up 30% of its $3.31B portfolio in Q4 2025.
  • Quadrant Capital Group opened 136 new positions and closed 104 in Q4 2025.
  • Quadrant Capital Group's portfolio value rose 7.6% quarter-over-quarter to $3.31B.

Based on Quadrant Capital Group's 13F filing for Q4 2025, filed 13 Feb 2026.